AGFG2

Across TCGA pan-cancer cohorts, AGFG2 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated AGFG2 data layer compared with 3 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher AGFG2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated AGFG2 expression acts as an unfavorable survival marker, although some lineages such as MESO and SKCM show a favorable association.

MESO, SKCM, and KIRC are the cancer types where AGFG2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.658	0.426	<.001	71	view →
SKCM	OS	Tertile	All	0.404	0.229	<.001	69	view →
KIRC	OS	Quartile	All	0.728	0.486	<.001	65	view →
ACC	OS	Median	II,III,IV	0.891	0.617	<.001	56	view →
UCS	OS	Tertile	III,IV	0.220	0.632	.004	48	view →
THCA	DFS	Median	All	0.887	0.766	<.001	43	view →
LGG	OS	Median	All	0.749	0.863	<.001	35	view →
READ	OS	Quartile	IV	0.374	0.995	.012	21	view →
BLCA	DFS	Quartile	III,IV	0.695	0.386	.016	13	view →
KIRP	OS	Median	III,IV	0.158	0.710	.019	12	view →
GBM	OS	Median	All	0.150	0.224	.008	12	view →
UVM	DFS	Quartile	All	0.819	0.486	.005	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

AGFG2–MESO (OS)

Open the MESO breakdown →